Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Is re-emerging superbug the next MRSA?

Is re-emerging superbug the next MRSA?

September 16, 2008

Loyola physicians warn little-known bacteria Clostridium difficile next emerging disease threat, killing 1,000s in the United States

MAYWOOD, Ill. - Dr. Ed Corboy had no idea what was afflicting his 80-year-old mother, Joan Corboy.




All he knew for certain was that since being treated for what was a routine diarrheal infection, she seemed to be wasting away and none of her doctors or other health specialists could explain why.

"She lost almost 55 pounds between July Fourth and Christmas in 2006," said Corboy, a resident of Wilmette. "She was so sick, so weak and despite the best care of her doctors, she was getting weaker. It was clear she was in big trouble."

Afraid that his mother was running out of time, Corboy called the Centers for Disease Control in Atlanta for advice. Dr. Clifford McDonald told him the infection his mother probably had was of the NAP1 type of the bacteria Clostridium difficile, a virulent strain of a common intestinal bacteria currently plaguing hospitals that now rivals the superbug Methicillin-resistant staphylococcus aureus (MRSA) as one of the top emerging disease threats to humans.

"Disease caused by Clostridium difficile can range from nuisance diarrhea to life-threatening colitis that could lead to the surgical removal of the colon, and even death," said Dr. Stuart Johnson, associate professor of medicine, division of infectious diseases, Loyola University Chicago Stritch School of Medicine. "It's a very hardy strain and it seems to persist."

C-diff, as it is better known, is a bacterium that was discovered in 1978 to be the cause of antibiotic-associated diarrhea and colitis, said Johnson, one of the world's top C-diff researchers and physicians, and who successfully treated Joan Corboy's infection. Although C-diff sickens about 500,000 Americans a year and has reached epidemic proportions in 38 states including Illinois, most people have not yet heard of it.

"I don't think that people appreciate the urgency and severity of this disease," said Dr. Dale Gerding, professor of medicine, division of infectious diseases, Stritch School of Medicine, and associate chief of staff for Research, Hines VA Hospital. "In the past, it was thought to be a nuisance illness. Now it is a fatal illness and a lot of physicians have not figured that out as yet."

Hospitals in Quebec have been particularly hard hit by C-diff. In the 12 hospitals affected, about 2,000 deaths were directly attributable to the antibiotic resistant strain between the 2003 and 2004. In the United Kingdom, deaths from C-diff leaped by 28% in 2007 to more than 8,000, according to the nation's Department of Health.

"What was surprising was not just the rates, but the number of severe cases," said Johnson, who helped treat Joan Corboy's illness.

Similar to MRSA, C-diff is an infection that is mainly acquired in a hospital or nursing home, although like MRSA there is some evidence that a community-acquired strain may be developing, according to the CDC.

"When a patient is in the hospital getting antibiotics for some type of infection, one of the potential complications is that the normal bacterium that lives in the colon is disturbed with that antibiotic. That makes you susceptible to an infection with Clostrium difficile," Johnson said. "The great majority of cases occur in people who have recently used antibiotics."

When C-diff is not actively dividing, it forms very tough spores that can exist on surfaces for months and years, making it very difficult to kill, Johnson said.

"Antibiotics are very effective against the growing form of the bacteria but it doesn't do anything to the spores," Johnson said. "If there are spores they can sit around like stealth bombs. Once the antibiotic is gone, these spores can germinate again and spread their toxins."

Since its discovery, C-diff has grown increasingly resistant to antibiotics, according to Johnson and Gerding, who has been studying the bacteria since 1980. Though it is appearing more often in younger people, those 65 years and older face a greater risk of developing infection from C-diff and has more severe outcomes and higher death rates. Relapse is common with about 25 percent of patient experiencing a second bout of disease within two months after their first. Patients who have had two or more episodes of disease have a 30 percent to 65 percent risk of another bout.

Symptoms of C-diff include profuse diarrhea and abdominal pain and distention of the abdomen. An infection is also frequently accompanied by fever, nausea and dehydration. In some rare cases blood may be present in the stool. The infection is spread by spores that contaminate the hospital environment and hands of healthcare workers who can transmit the spores to patients. The resistance of the spores to hospital cleaning agents and to alcohol hand disinfectants makes it extremely difficult to eradicate.

Loyola University Health System



Related Clostridium Current Events and Clostridium News Articles Clostridium Current Events and Clostridium News RSS Clostridium Current Events and Clostridium News RSS
Commentary warns of unexpected consequences of proton pump inhibitor use in reflux disease
Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases.

Deadly stomach infection rising in community settings, Mayo Clinic study finds
Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile is on the rise in outpatient settings.

Eating right, not supplements, is best at keeping your good bacteria healthy, dietitian says
Healthy eating, not supplements, is the best way to keep the good bacteria in your gut healthy, says a dietitian and researcher.

Structure of antibiotic ramoplanin reveals promising mechanism
With the "last resort" antibiotic Vancomycin now plagued by the first signs of bacterial resistance, a scientific collaboration centered at Duke University has identified how a candidate successor antibiotic known as Ramoplanin A2 can kill pathogenic bacteria by interrupting how they form their cell membranes.

Antibiotics take toll on beneficial microbes in gut
It's common knowledge that a protective navy of bacteria normally floats in our intestinal tracts. Antibiotics at least temporarily disturb the normal balance.

Newly discovered reactions from an old drug may lead to new antibiotics
A mineral found at health food stores could be the key to developing a new line of antibiotics for bacteria that commonly cause diarrhea, tooth decay and, in some severe cases, death.

Doctors identify patients at high risk of C. difficile
Doctors have developed and validated a clinical prediction rule for recurrent Clostridium difficile (C. difficile) infection that was simple, reliable and accurate, and can be used to identify high-risk patients most likely to benefit from measures to prevent recurrence. Their findings appear in a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

Poultry and diabetics at risk from gas gangrene bug
Gas gangrene, the notorious infectious disease of two world wars can still be a problem today.

Hospital infection control strategies for antibiotic-resistant organisms
Hand-washing, a clean environment, appropriate infection barriers and early identification of patients at high risk of colonization with a transmissible microorganism remain the essential measures to prevent and control infection.

What makes C-Diff superbug deadly?
A major breakthrough about the potentially deadly superbug Clostridium difficile (C-diff) could lead to new ways to combat the bacterium, according to a study to be published March 1 in the journal Nature.
More Clostridium Current Events and Clostridium News Articles
Handbook on Clostridia

Handbook on Clostridia
by Peter Duerre (Editor)

Clostridia is one of the largest bacterial genera with an enormous potential for biotechnical and medical applications. Despite this scientific, medical, and industrial interest, information on basic methods, biochemical fundamentals, clinical practice, industrial applications, and novel developments is scattered in a variety of research articles, reviews, and book chapters. The Handbook on Clostridia combines all these topics in a single volume. The author has taken a global approach, integrating into a seamless entity what until now have been two disparate and separate fields: Clostridia of biotechnological importance and Clostridia of medical importance.

Giantmicrobes C. Diff Clostridium Difficile [Toy]

Giantmicrobes C. Diff Clostridium Difficile [Toy]
by Giantmicrobes

Giant Microbes are soft, cute, durable, well made, educational, and just a lot of fun too! Each 5-to-7 inch doll is accompanied by an image of the real microbe it represents, as well as information about the microbe. Give it up for C. Diff, hospital's notorious gangsta.

CLOSTRIDIUM PERF A TOX 100ML 12 - 100 Milliliter

CLOSTRIDIUM PERF A TOX 100ML 12 - 100 Milliliter
by DURVET/NOVARTIS D

Clostridium Perfringens Type A Toxoid. For use in healthy cattle as an aid in the control of disease caused by the alpha toxin of clostridium perfringens. Shake well. Administer 2ml sq in the neck. Revaccinate in 2-4 weeks. Calves vaccinated prior to 5 months of age should be revaccinated at 5-6 months of age. Revaccinate annually or as recommended by your veterinarian.

Clostridium Botulinum: A Practical Approach to the Organism and Its Control in Foods

Clostridium Botulinum: A Practical Approach to the Organism and Its Control in Foods
by Chris Bell (Author), Alec Kyriakides (Author)

Details the causes of selected outbreaks and incidents of foodborne botulism and assesses the lessons that can be learned from them. Examines the characteristics of C.botulinum and identifies factors which make foods susceptible to contamination and organism growths. DLC: Botulism.

  Clostridium Difficile Test (25 per Pack)
by Marion Scientific

A 20 minute latex agglutination test for C. difficile associated diarrhea, 5 minutes hands on time, requires no instrument, excellent screening tes for stool specimenst, sensitivity found to be from 92 to 95%, negative predictive value 97 to 98%, controls included, performs 25 patient tests.

  Clostridium sporogenes - GroPro PLUS Growth Promotion Test Suspensions, NAMSA - Model GP-02 - Each
by Namsa

These ready-to-use microbial suspensions meet requirements for media growth promotion performance testing. All suspensions comply with requirements for a population of...

Clostridium

Clostridium
haploid 23 (Primary Contributor)



Clostridium Difficile - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References

Clostridium Difficile - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
by ICON Health Publications (Author)

In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.This book was created for medical professionals, students, and members of the general public who want to conduct medical research using the most advanced tools available and spending the least amount of time doing so.

Giant Microbes - C. Diff (Clostridium difficile) - Plush

Giant Microbes - C. Diff (Clostridium difficile) - Plush
by Giant Microbes

Give it up for C. Diff, hospital's notorious gangsta.

Gangrene (Clostridium perfringens) GIANTMicrobes Original

Gangrene (Clostridium perfringens) GIANTMicrobes Original
by GIANTMicrobes, Inc.

Gangrene (Clostridium perfringens) GIANTMicrobes Original - Gangrene sets in when you least expect it. This item is a GIANTmicrobes(R) Original (5-7" plush doll). GIANTMicrobes Original - GIANTMicrobes by Drew Oliver! [Product ID: GM-GANG1] [SKU: GMUS-PD-0295] [UPC: 874665008288]

© 2009 BrightSurf.com